Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heart Function Evolution Under Nivolumab in Melanoma and NSCLC
NCT03313544Phase 4Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Apr 2018
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of nivolumab in melanoma, non-small cell lung cancer (NSCLC), sponsored by Assistance Publique-Hôpitaux de Marseille. Status: unknown.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03313544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313544.